WallStSmart

DaVita HealthCare Partners Inc (DVA)vsMednax Inc (MD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 613% more annual revenue ($13.64B vs $1.91B). MD leads profitability with a 8.6% profit margin vs 5.5%. MD appears more attractively valued with a PEG of 0.24. MD earns a higher WallStSmart Score of 67/100 (B-).

DVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 8.7Quality: 4.3
Piotroski: 3/9Altman Z: 1.22

MD

Strong Buy

67

out of 100

Grade: B-

Growth: 3.3Profit: 6.5Value: 10.0Quality: 7.0
Piotroski: 5/9Altman Z: 1.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVAUndervalued (+11.7%)

Margin of Safety

+11.7%

Fair Value

$163.40

Current Price

$155.11

$8.29 discount

UndervaluedFair: $163.40Overvalued
MDUndervalued (+55.8%)

Margin of Safety

+55.8%

Fair Value

$48.58

Current Price

$21.19

$27.39 discount

UndervaluedFair: $48.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA3 strengths · Avg: 8.7/10
Return on EquityProfitability
64.8%10/10

Every $100 of equity generates 65 in profit

PEG RatioValuation
0.568/10

Growing faster than its price suggests

P/E RatioValuation
16.1x8/10

Attractively priced relative to earnings

MD4 strengths · Avg: 9.3/10
PEG RatioValuation
0.2410/10

Growing faster than its price suggests

P/E RatioValuation
10.9x10/10

Attractively priced relative to earnings

Return on EquityProfitability
20.3%9/10

Every $100 of equity generates 20 in profit

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.5%3/10

5.5% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

MD3 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.564/10

Distress zone — elevated risk

Market CapQuality
$1.82B3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-1.7%2/10

Revenue declined 1.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, PEG Ratio, P/E Ratio. PEG of 0.56 suggests the stock is reasonably priced for its growth.

Bull Case : MD

The strongest argument for MD centers on PEG Ratio, P/E Ratio, Return on Equity. PEG of 0.24 suggests the stock is reasonably priced for its growth.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : MD

The primary concerns for MD are Altman Z-Score, Market Cap, Revenue Growth.

Key Dynamics to Monitor

DVA carries more volatility with a beta of 0.93 — expect wider price swings.

DVA is growing revenue faster at 9.9% — sustainability is the question.

DVA generates stronger free cash flow (395M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MD scores higher overall (67/100 vs 66/100). Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Mednax Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

MEDNAX, Inc., provides neonatal, maternal-fetal, pediatric cardiology, and other pediatric subspecialties in the United States and Puerto Rico. The company is headquartered in Sunrise, Florida.

Visit Website →

Want to dig deeper into these stocks?